Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...